收稿日期: 2023-11-29
网络出版日期: 2024-05-15
基金资助
中华国际医学交流基金会呼吸疾病青年实用研究项目(Z2017242301)
Sarcopenia associated with chronic obstructive pulmonary disease
Received date: 2023-11-29
Online published: 2024-05-15
肌少症是一种进行性和全身性的骨骼肌疾病，是慢性阻塞性肺疾病（COPD）的重要肺外合并症。多项研究已证实合并肌少症的COPD患者气流阻塞和肺气肿程度更为严重、呼吸困难指数评分更高、生活质量和运动能力下降、频繁急性加重率和病死率升高。肌少症虽然作为COPD的合并症被提及多年，但目前的临床实践对其关注度和干预均不足，究其原因主要是其发病机制不明，药物治疗方案效果不佳所致。随着近年来对COPD合并肌少症的研究越来越多，本文对现阶段COPD合并肌少症的研究进展包括发病率、对临床结局的影响、发病机制、诊断标准和治疗进展进行综述，望能为COPD合并肌少症深入研究及早期干预提供一定的参考价值。
杨士芳 , 高兴林 , 李静 , 姬路鹏 . 慢性阻塞性肺疾病合并肌少症的研究进展[J]. 实用医学杂志, 2024 , 40(9) : 1181 -1185 . DOI: 10.3969/j.issn.1006-5725.2024.09.001
Sarcopenia is a progressive and systemic skeletal muscle disease and an important extrapulmonary complication of chronic obstructive pulmonary disease （COPD）. Multiple studies have confirmed that COPD patients with sarcopenia have more severe airflow obstruction and emphysema， higher dyspnea index scores， reduced quality of life and exercise capacity， frequent acute exacerbations， and increased mortality. Although sarcopenia has been mentioned as a complication of COPD for many years， current clinical practice has received insufficient attention and insufficient intervention. The main reason is that its pathogenesis is unknown and drug treatment regimens are ineffective. As more and more research has been done on COPD combined with sarcopenia in recent years， this article reviews the current research progress to pay attention to further research and early intervention， including new mechanisms， diagnostic criteria， and drug treatment progress.
Key words： chronic obstructive pulmonary disease; sarcopenia; progress
| 1 | SINGER J， YELIN E H， KATZ P P， et al. Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease： impact on exercise capacity and lower extremity function ［J］. J Cardiopulm Rehabil Prev， 2011， 31（2）： 111-119. doi:10.1097/hcr.0b013e3182033663 |
| 2 | CRUZ-JENTOFT A J， SAYER A A. Sarcopenia ［J］. Lancet， 2019， 393 （10191）， 2636-2646. doi:10.1016/s0140-6736(19)31138-9 |
| 3 | DIVO M J， CELLI B R， POBLADOR-PLOU B， et al. Chronic obstructive pulmonary disease （COPD） as a disease of early aging： evidence from the EpiChron cohort ［J］. PLoS One， 2018， 13： e0193143. doi:10.1371/journal.pone.0193143 |
| 4 | GóMEZ-MARTíNEZ M， RODRíGUEZ-GARCí A W， GONZáL-EZISLAS D， et al. Impact of Body Composotion and Sarcopenia on Mortality in Chronic Obstructive Pulmonary Disease Patients ［J］. J Cli Med， 2023， 12（4）： 1321. doi:10.3390/jcm12041321 |
| 5 | CHOI Y J， PARK H J， CHO J H， et al. Low Skeletal Muscle Mass and Clinical Outcomes in Chronic Obstructive Pulmonary Disease ［J］. Tuberc Respir Dis （Seoul）， 2023， 86（4）：272-283. doi:10.4046/trd.2023.0008 |
| 6 | MCDONALD M N， WOUTERS E F M， RUTTEN E， et al. It′s more than low BMI： prevalence of cachexia and associated mortality in COPD ［J］. Respir Res， 2019， 20： 100. doi:10.1186/s12931-019-1073-3 |
| 7 | CELLI B R， LOCANTORE N， TAL-SINGER R， et al. Emphysema and extrapulmonary tissue loss in COPD： a multi-organ loss of tissue phenotype ［J］. Eur Respir J， 2018， 51（2）：1702146. doi:10.1183/13993003.02146-2017 |
| 8 | BENZ E， TRAJANOSKA K， LAHOUSSE L， et al. Sarcopenia in COPD： a systematic review and meta-analysis［J］.Eur Respir Rev， 2019， 28（154）：190049. doi:10.1183/16000617.0049-2019 |
| 9 | SEPúLVEDA-LOYOLA W， OSADNIK C， PHU S， et al. Diagnosis， prevalence， and clinical impact of sarcopenia in COPD： a systematic review and meta-analysis［J］. J Cachexia Sarcopenia Muscle， 2020，11（5）：1164-1176. doi:10.1002/jcsm.12600 |
| 10 | ATTAWAY A H， WELCH N， HATIPOGLU U， et al. Muscle loss contributes to higher morbidity and mortality in COPD： an analysis of national trends［J］. Respirol， 2021， 26（1）：62-71. doi:10.1111/resp.13877 |
| 11 | ZHAO X， SU R， HU R， et al. Sarcopenia index as a predictor of clinical outcomes among older adult patients with acute exacerbation of chronic obstructive pulmonary disease： a cross-sectional study［J］. BMC Geriatr， 2023， 23（1）：89. doi:10.1186/s12877-023-03784-7 |
| 12 | BYUN M K， CHO E N， CHANG J， et al. Sarcopenia correlates with systemic inflammation in COPD ［J］. Int J Chron Obstruct Pulmon Dis， 2017， 12：669-675. doi:10.2147/copd.s130790 |
| 13 | WANG Y Q， LI P J， CAO Y Y， et al.Skeletal muscle mitochondrial dysfunction in chronic obstructive pulmonary disease： underlying mechanisms and physical therapy perspectives ［J］.Aging Dis， 2023， 14（1）：33-45. doi:10.14336/ad.2022.0603 |
| 14 | SANCHO-MU?OZ A， GUITART M， GUITART M， et al. Deficient muscle regeneration potential in sarcopenic COPD patients： Role of satellite cells ［J］. J Cell Physiol， 2021， 236（4）：3083-3098. doi:10.1002/jcp.30073 |
| 15 | MONTES DE OCA M， TORRES S H， DE SANCTIS J， et al. Skeletal muscle inflammation and nitric oxide in patients with COPD ［J］. Eur Respir J， 2005， 26（3）：390-397. doi:10.1183/09031936.05.00107404 |
| 16 | MENON M K， HOUCHEN L， SINGH S J，et al. Inflammatory and satellite cells in the quadriceps of patients with COPD and response to resistance Training ［J］. Chest， 2012， 142（5）：1134-1142. doi:10.1378/chest.11-2144 |
| 17 | GURRIARAN-RODRIGUEZ U， SANTOS-ZAS I， GONZALEZ-SANCHEZ J，et al. Action of obestatin in skeletal muscle repair：stem cell expansion，muscle growth， and microenvironment remodeling ［J］. Mol Ther， 2015， 23（6）：1003-1021. doi:10.1038/mt.2015.40 |
| 18 | LAKSHMAN KUMAR P， WILSON A C， ROCCO A， et al. Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease ［J］. J Cachexia Sarcopenia Muscle， 2021， 12（6）：1803-1817. doi:10.1002/jcsm.12782 |
| 19 | ATTAWAY A H， BELLAR A， WELCH N， et al. Gene polymorphisms associated with heterogeneityand senescence characteristics of sarcopenia in chronic obstructive pulmonary disease ［J］. J Cachexia Sarcopenia Muscle， 2023， 14（2）：1083-1095. doi:10.1002/jcsm.13198 |
| 20 | TAN Z， ZHAO M， LI J， et al. Myostatin is involved in skeletal muscle dysfunction in chronic obstructive pulmonary disease via Drp-1 mediated abnormal mitochondrial division ［J］. Ann Transl Med， 2022， 10（4）： 162. doi:10.21037/atm-22-377 |
| 21 | LEDUC-GAUDET J P， REYNAUD O， HUSSAIN S N， et al. Parkin Overexpression Protects from Ageing-Related Loss of Muscle Mass and Strength ［J］. J Physiol， 2019， 597（7）： 1975-1991. doi:10.1113/jp277157 |
| 22 | 左玉强，柳青，高志红，等. L3椎体平面骨骼肌和脂肪化程度与老年肌少症关系的CT定量研究 ［J］. 实用医学杂志， 2021， 37 （11）： 1470-1475. doi:10.3969/j.issn.1006-5725.2021.11.020 |
| 23 | PATEL S， MADDOCKS M， MAN W D.Exercise Training in COPD： FITT for Purpose ［J］. Chest， 2020， 158（1）：9-10. doi:10.1016/j.chest.2020.02.040 |
| 24 | REMELLI F， VITALI A， ZURLO A， et al.Vitamin D deficiency and sarcopenia in older persons ［J］. Nutrients， 2019， 11（12）：2861. doi:10.3390/nu11122861 |
| 25 | PASSEY S L， HANSEN M J， BOZINOVSKI S， et al. Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease ［J］. Pharmacol Ther， 2016， 166：56-70. doi:10.1016/j.pharmthera.2016.06.013 |
| 26 | POLKEY M I， PRAESTGAARD J， BERWICK A， et al. Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial ［J］. Am J Respir Crit Care Med， 2019， 199（3）：313-320. doi:10.1164/rccm.201802-0286oc |
/
| 〈 |
|
〉 |